SCHEMBL4707161

SCHEMBL4707161

CCOC(=O)c1oc2nc(N(C)C)c3c(c2c1N)CC(C)(C)OC3

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 18/20 0.79
KDM4E B2RXH2 17/20 0.79
HPGD P15428 12/20 0.79
HSD17B10 Q99714 7/20 0.79
TSHR P16473 3/20 0.74
RECQL P46063 1/20 0.74
GAA P10253 4/20 0.53
MAPK1 P28482 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
MAPT P10636 5/20 0.51
HTT P42858 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
POLB P06746 2/20 0.50
KMT2A Q03164 2/20 0.50
HIF1A Q16665 1/20 0.50
XBP1 P17861 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708892 0.86 ALDH1A1 (0.68) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4707815 0.82 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4706598 0.81 KDM4E (0.71) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4711537 0.72 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL24256901 0.69 KDM4E (0.77) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL5015905 0.68 KDM4E (0.64) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4708645 0.68 KDM4E (0.54) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4709157 0.67 KDM4E (0.75) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4914020 0.66 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL19740957 0.66 KDM4E (0.76) ALDH1A1KDM4EHPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221096-A1 Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2008-09-11 US disclosed
EP-1913003-A1 NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES Laboratorios Almirall, S.A. (ES) 2008-04-23 EP disclosed
WO-2007017078-A1 NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221096-A1 Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives NR1H2, CBR3, NR4A1 ALDH1A1 2625/4885KDM4E 3618/4885HPGD 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.